Eli Lilly on Wednesday said it will pour an additional $4.5 billion into expanding two of its manufacturing sites in Lebanon, Indiana, while officially cutting the ribbon on a new genetic-medicine plant on the same campus. The company cast the move as part of a broader, multiyear push to beef up U.S. production of advanced therapies and active pharmaceutical ingredients, as local leaders touted the deal as another win for the LEAP research district northwest of Indianapolis.
Big boost for Lebanon campus
According to Reuters, the new $4.5 billion commitment covers two of the three sites at Lilly's Lebanon complex and pushes the drugmaker's total Indiana capital commitments since 2020 to more than $21 billion. The outlet reports that the latest funds are earmarked for the Lilly Lebanon API project and the Lilly Lebanon Advanced Therapies facility, which the company formally opened on Wednesday.
What Lilly will make in Lebanon
In a press release from Eli Lilly, company officials said the Lebanon API site is expected to produce injectable medicines including Mounjaro and Zepbound. The newly opened Advanced Therapies facility, they added, is built to handle both clinical and commercial-scale genetic medicines. The release also notes that the expansion will support production of Foundayo, Lilly's recently approved oral weight-loss pill, along with retatrutide, an investigational triple-hormone candidate. "Lilly's legacy of firsts in Indiana continues today, and the best measure of that legacy is what we do next," David A. Ricks, Lilly's chair and CEO, said in the statement.
What it means for the LEAP district
The Lebanon complex spans roughly 600 acres inside the state's LEAP Research & Innovation District and has emerged as the centerpiece of Lilly's U.S. manufacturing buildout, FiercePharma reports. Coverage of the announcement also highlighted a company-cited analysis from Indiana University's Kelley School of Business estimating that Lilly accounts for about 70% of Indiana's pharmaceutical GDP and that each Lilly job supports more than two additional positions across the state.
Part of a bigger reshoring push
Lilly says the Lebanon projects are one piece of a larger U.S. manufacturing play. Company materials indicate its capital expansion commitments in the United States since 2020 now top $50 billion. The firm's investor documents and prior announcements describe a multistate buildout of API and injectable capacity intended to reshore critical parts of the drug supply chain and create thousands of construction and manufacturing jobs, per Eli Lilly.
Company materials state that the Lebanon API facility is slated to open in 2027 and, by Lilly's account, will be the largest API production site in U.S. history. Local officials said the project will trigger upgrades to roads, water infrastructure and power systems, along with a wave of construction work and long-term manufacturing jobs for the region. For the full company statement and independent coverage, see Eli Lilly and reporting from Reuters.
